Transendocardial autologous bone marrow mononuclear cell injection in ischemic heart failure : Postmortem anatomicopathologic and immunohistochemical findings

Cell-based therapies for treatment of ischemic heart disease are currently under investigation. We previously reported the results of a phase I trial of transendocardial injection of autologous bone marrow mononuclear (ABMM) cells in patients with end-stage ischemic heart disease. The current report...

Full description

Saved in:
Bibliographic Details
Published in:Circulation (New York, N.Y.) N.Y.), 2005-07, Vol.112 (4), p.521-526
Main Authors: DOHMANN, Hans F. R, PERIN, Emerson C, DUTRA, Helio S, ASSAD, Joao A. R, CASTELLO-BRANCO, Rodrigo V, DRUMMOND, Cantidio, DOHMANN, Hans J. F, WILLERSON, James T, BOROJEVIC, Radovan, TAKIYA, Christina M, SILVA, Guilherme V, SILVA, Suzana A, SOUSA, Andre L. S, MESQUITA, Claudio T, ROSSI, Maria-Isabel D, PASCARELLI, Bernardo M. O, ASSIS, Isabella M
Format: Article
Language:English
Subjects:
Biological and medical sciences
Blood and lymphatic vessels
Blood vessels and receptors
Bone Marrow Cells - cytology
Bone Marrow Transplantation
Cardiology. Vascular system
Desmin - analysis
Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous
Drug toxicity and drugs side effects treatment
Fundamental and applied biological sciences. Psychology
Heart Failure - pathology
Heart Failure - therapy
Humans
Immunohistochemistry
Male
Medical sciences
Middle Aged
Myocardial Ischemia - pathology
Myocardial Ischemia - therapy
Myocardium - pathology
Neovascularization, Physiologic
Pharmacology. Drug treatments
Stem Cell Transplantation
Tomography, Emission-Computed, Single-Photon
Toxicity: blood
Transplantation, Autologous
Vertebrates: cardiovascular system
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cell-based therapies for treatment of ischemic heart disease are currently under investigation. We previously reported the results of a phase I trial of transendocardial injection of autologous bone marrow mononuclear (ABMM) cells in patients with end-stage ischemic heart disease. The current report focuses on postmortem cardiac findings from one of the treated patients, who died 11 months after cell therapy. Anatomicopathologic, morphometric, and immunocytochemical findings from the anterolateral ventricular wall (with cell therapy) were compared with findings from the interventricular septum (normal perfusion and no cell therapy) and from the inferoposterior ventricular wall (extensive scar tissue and no cell therapy). No signs of adverse events were found in the cell-injected areas. Capillary density was significantly higher (P
ISSN:0009-7322
1524-4539
DOI:10.1161/CIRCULATIONAHA.104.499178